News Pharma Industry

Krsnaa Diagnostics’ IPO garnered investor interest. Can it become the next Dr PathLabs, Thyrocare?


Concept by Priyanka Salve and Muhabit ul haq

Synopsis

Krsnaa Diagnostics’ IPO was oversubscribed 64.4x, second only to Thyrocare’s 73x. It has caught the fancy of retail investors. The company’s differentiated model — a strong presence in radiology, in-hospital centres, and government contracts — sets it apart from its peers. Does Krsnaa have the potential to become a multi-bagger?

The diagnostics space has been seeing a lot of action since the Covid-19 outbreak. Shares of listed firms such as Dr Lal PathLabs, Metropolis Healthcare, and Thyrocare Technologies have surged between 160% and 200% so far since March 2020. There is now a greater realisation about the importance of diagnostics in preventing and managing diseases. This is a big positive for the industry, which is still largely fragmented and under-penetrated in

  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • PRINT
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Special Offer on ET Prime

Get Flat 20% Off

ON ET PRIME MEMBERSHIP

Get Offer

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise



Source link